top of page

About OsciFlex

OsciFlex LLC was founded in 2017 by John Welsh, PhD and Mark Kahn, MD at the University of Pennsylvania. Dr. Welsh and Dr. Kahn uncovered key findings related to the molecular pathology of venous thrombosis. OsciFlex was founded to leverage novel science to create improved therapies for patients to prevent and treat venous disease. 

Meet The Team

Mark-Kahn-MD-2.jpg

Mark Kahn,MD

Chief Medical Officer and Co-Founder

  • LinkedIn
John-Welsh-OsciFlex.jpg

John Welsh, PhD

CEO and Co-Founder

  • LinkedIn

A novel approach to preventing Venous thromboembolism (VTE) 

New treatments for chronic venous insufficiency

Therapies to prevent physical complications from prolonged immobility

Core Values

Objectives

Company Milestones

2019:  

  • NSF SBIR PHASE I Grant

  • NIH STTR PHASE 1 Grant

  • Penn Cardiovascular Institute “Dream Team” Award

  • Penn Health Tech Award

  • Basic science publication accept to top journal (JCI 2019)

2021 / 2022:  

  • NIH SBIR Phase II Grant awarded

  • File initial patent application for rapid cycling compression technology

  • NSF SBIR Phase II Grand awarded

2024:

  • Raised private seed round of funding​

  • Completed out-licensing of rapid cycling compression technology

Core Values

2025:

  • Raised additional private funding

  • Filed initial patent applications for two additional devices 

Core Values

Contact

OsciFlex LLC

Pennovation Center
3401 Grays Ferry Ave
Philadelphia, PA, 19146
Ph: (609) 977-7258

Be in the Know

Reach out to learn more about Osciflex and our latest developments. 

Thanks for submitting!

Follow us on

© 2023 by Osciflex.

bottom of page